

Profile #2643

Profile #2643 - St. Anna Kinderkrebsforschung e.V - Austria

Date: 2009/08/06	Deadline: 2013/12/31
------------------	----------------------

Contact

Organisation	St. Anna Kinderkrebsforschung e.V	Department	Children's Cancer Research Institute
Contact person	Valdés Rodríguez, Dr. Karla		
Email	karla.valdes-rodriguez@ccri.at		
Address	Zimmermannplatz 10		
Postcode	1090	City	Vienna
Country	Austria		
Telephone	+43(1)40470-4440	Fax	
Website	http://www.kinderkrebsforschung.at/ ; www.ccri.at		

Organisation

Type:	Research Organisation & Universities
Is a Small and Medium Sized Enterprise (SME)? NO	
Number of Employees	83
Description of research activity:	<p>Selected research interests:</p> <ul style="list-style-type: none">- Immunological procedures in the hematopoietic stem cell transplantation and development of procedures for therapeutic intervention- Indoleamine 2,3-dioxygenase mediated tolerance- Hematopoietic regeneration- Monitoring of donor-recipient chimerism- Optimization of leukocyte apheresis- Interaction of the immune system with tumour tissue- Dendritic cells based cancer immune therapy- Cellular and molecular biology of immune regulation by dendritic cells- Signal transduction inhibitors for ALL therapy- Mechanistic systems in tumour development- Monitoring of receptor tyrosine kinase signaling for therapy- Chromosome translocations in leukaemia and sarcoma: detection and mechanistic studies- Systems biology of tumour development

Former participation in an FP European project? YES

Project title / Acronym:

FP5, FP6, FP7

Activities performed::	<p>FP7: DIRECT (CSA) - Coordination.</p> <p>FP6: EET-Pipeline (IP) - Partner Dentritophages (STREP) - Partner Siopen E-Net (NoE) – Partner DC-Thera (NoE) - Partner</p> <p>FP5 Eurochimerism – Coordinator</p>
-------------------------------	--

Research topics

- HEALTH.2010.1.4-1: Translational research on cell-based immunotherapy. FP7-HEALTH-2010-SINGLE-STAGE
- HEALTH.2010.2.4.1-2: Structuring translational cancer research between cancer research centres in Europe. - FP7-HEALTH-2010-SINGLE-STAGE
- HEALTH.2010.2.4.1-3: Structuring clinical research in paediatric and adolescent oncology in Europe. FP7-HEALTH-2010-SINGLE-STAGE
- HEALTH.2010.4.2-1.: Off-Patent Medicines for Children. - FP7-HEALTH-2010-SINGLE-STAGE
- HEALTH.2010.4.2-2: International Paediatric initiative. - FP7-HEALTH-2010-SINGLE-STAGE

Expertise/commitment offered

Keywords specifying the expertise:	Children, pediatric cancer, diagnostics, clinical, neuroblastoma, leukemia, Ewing sarkoma, histiocytosis, dendritic cells, adenovirus, stem cells, tumour, immunology, bioinformatics, residual diseases, mycosis, indoleamine, hematopoiesis, haematology,
---	---

Description of the expertise:

Research groups:
Tumour Biology - Immunologic Diagnostics - Tumour Immunology - Biology of Stem Cells - Transplant Immunology - Molecular Biology - Bioinformatics - Clinical Studies and Statistics - Molecular Microbiology - Biology of Leukaemia - Genetics of Leukaemia.

Specific focus on following diseases:
Leukaemia (ALL, AML, CML, minimal residual disease) - Neuroblastoma - Ewing Sarkoma - Lymphoma - Mycosis and viral infections in immunocompromised patients, Langerhans cell histiocytosis.

Selection on validated methods and technologies:
FISH - Array CGH - qualitative and quantitative PCR test methods - Flow-Cytometry - FACS - cytogenetic analysis, basic molecular biology techniques.

Paediatric Reference laboratories for:
- Chronic myelogenous leukaemia
- Acute lymphoblastic leukaemia
- Acute myelogenous leukaemia
- Minimal rest disease of acute lymphoblastic leukemia
- Lymphoma
- Ewing sarcoma
- Neuroblastoma

JACIE certified laboratories for:
- Flow cytometric quantification
- Flow cytometric monitoring of engraftment
- Flow cytometric enumeration of leukocyte subtypes
- Flow cytometric cell sorting of cells from different tissue sources and blood

GMP standards for above mentioned JACIE certified methodologies and for
- Cell depletion prior to bone marrow transplantation
- Plasma depletion from bone marrow or apheresis products
- Cytopreservation and storage logistics of autologous allogenic blood products
- In vitro generation of dendritic cells generating anti CMV-specific immunity
- Manufacturing and quality control of dendritic cell based cancer vaccines for clinical trials (currently phase II)

Clinical Collaboration

Leo Kager

National Coordinator for EURAMOS-1 (Osteosarcoma; research, e.g., Primary metastatic osteosarcoma; Kager et al. J Clin Oncol. 2003) and SIOP 2001/GPOH (Wilms Tumour, research e.g., Kager et al. Klin Päd. 1999) trials in Austria; National Coordinator for rare malignancies in children (GPOH trial; e.g., Pleuropulmonary blastoma, Kager et al. Monatschr Kinderheilkd 1998, Alveolar soft part sarcoma, Kager et al. Monatschr Kinderheilkd 1999).

Current research focuses on:

a) Pharmacogenomics to improve MTX therapy in lymphoid malignancies (Sorich et al. PLoS Med 2008; Pottier et al. Exp Review Clin Pharm 2008; Kager Monatsschr Kinderheilkd 2008; Kager & Evans. Pharmacogenomics in Hematol Diseases. Eds. Hoffman et al. 2008; Cheok et al. Semin Hematol. 2009; Cheok, Evans & Kager J Pediatr Hematol Oncol. 2009, Kager MEMO 2009; Kager JBUON 2009; Kager & Evans. Pharmacogenomics. Eds. Provan & Gribben 2010).

b) Osteosarcoma (previous research: Primary metastatic osteosarcoma; Kager et al. J Clin Oncol. 2003, Skip metastases in osteosarcoma, Kager et al. J Clin Oncol. 2006) current research on very young children with osteosarcoma; Kager et al. 2009 submitted to Pediatrics.

c) Acute lymphoblastic leukemia (Kager et al. Hematologica 2007); E2A-PBX1 positive ALL

d) Rare non-malignant diseases (e.g., Immunodeficiency, Dobbs et al. J Immunology 2007; Thiamine-responsive megaloblastic anemia (TRMA), manuscript in preparation - collaboration with Dr. Neufeld, Boston; etc.)

Susanne Matthes

Clinical research in the context of pediatric allogeneic stem cell transplantation

Main fields of interest:

Immunoreconstitution

Viral infections, adoptive transfer of virus-specific CTLs

Commitment offered	Clinical Collaboration: develop, therapy protocols, invest. of novel cancer therapeutics
---------------------------	--

Expectations

Term commitment:	Medium (1 to 3 years)
Expected results for your organisation:	<p>Participate as partners in the current HEALTH call and in the call "Research for SMES".</p> <p>Enforce the international collaboration with excellent research institutions and the industry, within and besides EU-projects</p> <p>Train foreign scientists in our research facilities and train our scientists in partner institutions</p> <p>Exchange knowledge with participant organisations</p> <p>Further contribute to the development of novel therapy and diagnostics approaches in the field of paediatric cancer</p>